- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Inefficient Market Opportunities
Global Pharmaceuticals & Biotech Inefficient Market Opportunities
Results
6
Less coverage brings about more information asymmetry and more opportunities to buy mispriced stocks. Companies valued at less than US$500M with low PE and PEG.
6 companies
Zevra Therapeutics
Market Cap: US$469.0m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$8.17
7D
-6.9%
1Y
-3.2%
SIGA Technologies
Market Cap: US$462.6m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$6.46
7D
5.0%
1Y
4.5%
Abeona Therapeutics
Market Cap: US$290.5m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$5.08
7D
-1.0%
1Y
-13.8%
Protalix BioTherapeutics
Market Cap: US$144.0m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$1.74
7D
0%
1Y
-0.6%
hVIVO
Market Cap: UK£44.9m
Operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America.
HVO
UK£0.066
7D
37.5%
1Y
-68.2%
Oncodesign Precision Medicine Société anonyme
Market Cap: €7.2m
A biopharmaceutical company, engages in the precision medicine business.
ALOPM
€0.40
7D
-2.7%
1Y
-59.2%